Pimecrolimus para mastocitosis.
Topical Pimecrolimus for Cutaneous Mastocytosis
TAKE-HOME MESSAGE
The authors of this study determined the safety and effectiveness of topical pimecrolimus cream for the treatment of cutaneous mastocytosis (CM). The study included 18 pediatric patients with a total of 146 CM lesions, who were treated with pimecrolimus 1% cream twice daily for a mean treatment time of 8.3 months. Of these patients, 26.7% had complete disappearance of their lesions and 67% had fading or developed post-inflammatory hyperpigmentation. Furthermore, 47% became macular and 16.4% showed partial flattening. The Darier sign became negative in 82% of patients. No side effects were observed.
Pimecrolimus may be a safe and effective treatment for cutaneous mastocytosis.
– Anna A. Wile, MD
Abstract
BACKGROUND
Most cases of paediatric cutaneous mastocytosis (CM) occur before the age of 2 years, and regression occurs in only 67% of children. Given the absence of any specific therapy, CM is usually treated symptomatically. A few publications have reported the beneficial effect of calcineurin inhibitors for CM.
AIM
We sought to evaluate the clinical effectiveness and safety profile of topical pimecrolimus cream for the treatment of CM.
METHODS
We performed a retrospective study of all diagnosed cases of CM treated with topical pimecrolimus 1% cream between 2013 and 2015. All patients were evaluated in a paediatric dermatology unit of a tertiary medical centre. Epidemiological, clinical and treatment data, including effectiveness and safety, were reviewed.
RESULTS
In total, 18 children (11 male, 7 female; age range 3-42 months) with CM were evaluated. Of the 146 treated lesions, 39 (26.7%) disappeared and 98 (67%) faded or developed postinflammatory hyperpigmentation. Of the 119 papular lesions, 24 (16.4%) showed partial flattening and 56 (47%) became macular. Darier sign became negative in 14 (82%) of 17 patients. No topical or systemic complications were observed.
CONCLUSIONS
Topical therapy with pimecrolimus 1% cream should be considered in the treatment of CM.
Additional Info
Topical Pimecrolimus for Paediatric Cutaneous Mastocytosis
Clin Exp Dermatol 2018 Feb 20;[EPub Ahead of Print], J Mashiah, A Harel, C Bodemer, S Hadj-Rabia, I Goldberg, E Sprecher, A Kutzposted by dermatica at
April 09, 2018
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home